Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection
Copyright © 2018. Published by Elsevier Inc..
With DNA vaccines, it is important to monitor the movement of transfectants and to overcome immune deviations. We used a pCMV-LacZ plasmid (expressing β-galactosidase) and a pcDNA-hNIS plasmid (expressing the human sodium/iodide symporter [hNIS] gene) as non-secreted visual-imaging markers. Transfectants carrying the hNIS or LacZ gene migrated to peripheral lymphoid tissues. hNIS-expressing cells were observed specifically in the LNs and spleen. Anti-β-galactosidase was detected in LacZ DNA immunized mice after boosting twice, suggestive of Th2 humoral immune responses. Antibody isotyping defined the humoral immune response. A dominant IgG2a type occurred in hNIS-immunized mice in ELISAs. IgG2a/IgG1 ratios increased after hNIS DNA vaccination. High levels of INF-γ-secreting cells were identified in ELISpot and increased IFN-γ levels were found in cytokine ELISAs. Tumor growth decreased in hNIS DNA-immunized mice. In conclusion, humoral immune responses switched to the Th1 cellular immune response, even though we administered plasmid DNA by intra dermal injection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:329 |
|---|---|
| Enthalten in: |
Cellular immunology - 329(2018) vom: 01. Juli, Seite 17-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Son, Hye-Youn [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.06.2019 Date Revised 13.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cellimm.2018.04.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283021349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283021349 | ||
| 003 | DE-627 | ||
| 005 | 20231225035405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cellimm.2018.04.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0943.xml |
| 035 | |a (DE-627)NLM283021349 | ||
| 035 | |a (NLM)29653690 | ||
| 035 | |a (PII)S0008-8749(18)30039-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Son, Hye-Youn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protective efficacy of a plasmid DNA vaccine against transgene-specific tumors by Th1 cellular immune responses after intradermal injection |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2019 | ||
| 500 | |a Date Revised 13.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018. Published by Elsevier Inc. | ||
| 520 | |a With DNA vaccines, it is important to monitor the movement of transfectants and to overcome immune deviations. We used a pCMV-LacZ plasmid (expressing β-galactosidase) and a pcDNA-hNIS plasmid (expressing the human sodium/iodide symporter [hNIS] gene) as non-secreted visual-imaging markers. Transfectants carrying the hNIS or LacZ gene migrated to peripheral lymphoid tissues. hNIS-expressing cells were observed specifically in the LNs and spleen. Anti-β-galactosidase was detected in LacZ DNA immunized mice after boosting twice, suggestive of Th2 humoral immune responses. Antibody isotyping defined the humoral immune response. A dominant IgG2a type occurred in hNIS-immunized mice in ELISAs. IgG2a/IgG1 ratios increased after hNIS DNA vaccination. High levels of INF-γ-secreting cells were identified in ELISpot and increased IFN-γ levels were found in cytokine ELISAs. Tumor growth decreased in hNIS DNA-immunized mice. In conclusion, humoral immune responses switched to the Th1 cellular immune response, even though we administered plasmid DNA by intra dermal injection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Boosting | |
| 650 | 4 | |a DNA vaccine | |
| 650 | 4 | |a IgG2a | |
| 650 | 4 | |a Intradermal (i.d.) | |
| 650 | 4 | |a Th1 | |
| 650 | 4 | |a Tumor retardation | |
| 650 | 4 | |a pCMV-LacZ | |
| 650 | 4 | |a pcDNA-hNIS | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Symporters |2 NLM | |
| 650 | 7 | |a Vaccines, DNA |2 NLM | |
| 650 | 7 | |a sodium-iodide symporter |2 NLM | |
| 650 | 7 | |a 4XE5NDT4K1 |2 NLM | |
| 700 | 1 | |a Apostolopoulos, Vasso |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, June-Key |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Chul-Woo |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Ji-Ung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular immunology |d 1970 |g 329(2018) vom: 01. Juli, Seite 17-26 |w (DE-627)NLM000001821 |x 1090-2163 |7 nnns |
| 773 | 1 | 8 | |g volume:329 |g year:2018 |g day:01 |g month:07 |g pages:17-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cellimm.2018.04.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 329 |j 2018 |b 01 |c 07 |h 17-26 | ||